NT-proBNP as a prognostic factor of mortality in patients hospitalized by covid-19 during the period january-october 2021

Abstract

The 2019 Coronavirus (COVID-19) generated a high mortality, which describes cardiovascular, inflammatory and thrombotic complications expressed and diagnosed through the elevation of cardiac biomarkers, such as the N-Terminal portion of Pro-BNP (NT-ProBNP), being associated elevation with mortality. A non-experimental retrospective cohort study was designed to determine the prognostic utility of NT-proBNP in mortality in COVID-19 patients hospitalized from january to october 2021 at Centro Médico Docente La Trinidad, for which the medical records of patients with COVID-19 with NT ProBNP levels, cardiac biomarkers and follow-up for 60 days from the onset of their symptoms. The medical records of 46 patients between 42 and 93 years old with an average of 69 years old, 24 men; Chi square test was applied (X2 0.7466 and p= 0.3875) and calculation of Relative Risk of 1.65 and a Relative Risk Reduction of 61.5%, showing that those patients with this elevated marker almost doubled their risk of mortality with respect to those who did not have elevation with NT-ProBNP, a statistically significant association was only demonstrated between mortality and elevation of NT-proBNP in patients with endocrinological pathology (p=0.021) and elevation of ultrasensitive troponin I (OR 39 CI 95% 2.14-713); no association was demonstrated with the rest of the clinical variables. The sample does not allow any predictive mathematical model and therefore its predictive value could not be concluded statistically, so it is recommended to carry out a prospective study that controls the variables studied.